2.34
price up icon4.00%   0.09
after-market Dopo l'orario di chiusura: 2.38 0.04 +1.71%
loading
Precedente Chiudi:
$2.25
Aprire:
$2.24
Volume 24 ore:
302.26K
Relative Volume:
2.15
Capitalizzazione di mercato:
$65.24M
Reddito:
-
Utile/perdita netta:
$-14.14M
Rapporto P/E:
-2.5435
EPS:
-0.92
Flusso di cassa netto:
$-12.64M
1 W Prestazione:
+17.59%
1M Prestazione:
+15.84%
6M Prestazione:
+10.90%
1 anno Prestazione:
+11.96%
Intervallo 1D:
Value
$2.24
$2.47
Intervallo di 1 settimana:
Value
$1.89
$2.47
Portata 52W:
Value
$1.26
$2.71

Immix Biopharma Inc Stock (IMMX) Company Profile

Name
Nome
Immix Biopharma Inc
Name
Telefono
(888) 958-1084
Name
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Name
Dipendente
21
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-09
Name
Ultimi documenti SEC
Name
IMMX's Discussions on Twitter

Confronta IMMX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IMMX
Immix Biopharma Inc
2.34 55.48M 0 -14.14M -12.64M -0.92
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Immix Biopharma Inc Borsa (IMMX) Ultime notizie

pulisher
May 29, 2025

Immix Biopharma — Positive newsflow continues for NEXICART-2 - Smartkarma

May 29, 2025
pulisher
May 23, 2025

Immix Biopharma accelerates NEXICART-2 trial enrollment By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Sto - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World

May 23, 2025
pulisher
May 22, 2025

Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune

May 22, 2025
pulisher
May 21, 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire

May 21, 2025
pulisher
May 19, 2025

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Immix Biopharma — Steady progress in Q125 - Smartkarma

May 19, 2025
pulisher
May 05, 2025

Immix Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 01, 2025

Immix Biopharma (IMMX) to Release Earnings on Thursday - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - simplywall.st

Apr 30, 2025
pulisher
Apr 23, 2025

Immix Biopharma Announces Oral Presentation of NXC-201 Phase 1/2 Trial Data at ASCO 2025 - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Groundbreaking CAR-T Therapy for AL Amyloidosis: First US Trial Data Earns Prestigious ASCO Spotlight - Stock Titan

Apr 23, 2025
pulisher
Apr 03, 2025

Immix Biopharma — All eyes on NEXICART-2 - Smartkarma

Apr 03, 2025
pulisher
Mar 28, 2025

Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 25, 2025

Immix Biopharma Inc. (IMMX) reports earnings - Quartz

Mar 25, 2025
pulisher
Mar 20, 2025

Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 13, 2025

Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma

Mar 13, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Mar 12, 2025
pulisher
Mar 04, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World

Mar 04, 2025
pulisher
Feb 13, 2025

HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis - OncLive

Feb 13, 2025
pulisher
Feb 12, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis - CGTLive™

Feb 10, 2025
pulisher
Feb 10, 2025

Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201 - TipRanks

Feb 10, 2025
pulisher
Feb 10, 2025

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Immix Biopharma Receives FDA RMAT Designation For NXC-201 -February 10, 2025 at 10:15 am EST - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Think Lucid Group is Expensive? This Chart Might Change Your Mind. - The Globe and Mail

Feb 10, 2025
pulisher
Feb 10, 2025

Immix Biopharma Receives FDA Regenerative Medicine Advanced - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment - StockTitan

Feb 10, 2025
pulisher
Feb 06, 2025

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - The Globe and Mail

Feb 06, 2025
pulisher
Feb 06, 2025

Immix Biopharma : Presentation (IMMX Corporate presentation February 2025) - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

Is Qualcomm Stock a Buy Even Without Huawei Deal? - The Globe and Mail

Feb 06, 2025
pulisher
Feb 05, 2025

Several Insiders Invested In Immix Biopharma Flagging Positive News - Yahoo Finance

Feb 05, 2025
pulisher
Jan 20, 2025

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December - MarketBeat

Jan 20, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Has $224,000 Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Jan 14, 2025
pulisher
Jan 10, 2025

FY2024 EPS Estimate for Immix Biopharma Lowered by Analyst - Defense World

Jan 10, 2025

Immix Biopharma Inc Azioni (IMMX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):